NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare ConferenceCompany highlights ongoing clinical developments in traumatic brain injury (TBI) therapeutics and non-invasive cancer screening, sparking key vendor collaboration discussions.
NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online DiscussionORLANDO, FL / ACCESS Newswire / August 6, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI) ("NexTel" or the "Company") is issuing a clarification regarding statements made during an audio stream hosted yesterday afternoon with @SuperRobotGX.
NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLCStrategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA Orphan Drug Designation
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion AnimalsCompany targets a growing $1.2B+ North American pet oncology market leveraging proprietary exosome-based diagnostic technologies.
